iBio Reports Q1 Fiscal Year 2026 Financial Results and Provides Corporate Update

Core Insights - iBio, Inc. has strengthened its cash position and extended its operational runway into the fourth quarter of fiscal year 2027 after closing a public offering with potential gross proceeds of up to $100 million [1][7] - The company presented promising non-human primate data for its Activin E antibody, IBIO-610, which may allow for only twice-yearly dosing for obesity treatment, indicating a significant advancement in patient compliance and therapeutic potential [2][7] Financial Results - For the fiscal quarter ended September 30, 2025, iBio reported revenue of $0.1 million, compared to no revenue for the same period in 2024 [7][10] - Research and Development (R&D) expenses increased to $3.6 million from $1.3 million year-over-year, attributed to advancing preclinical research activities [7][10] - General and Administrative expenses decreased to approximately $2.5 million from $2.8 million, mainly due to reduced professional expenses and legal fees [7][10] - The net loss for the quarter was $5.7 million, compared to a net loss of $4.0 million in the prior year [10] Corporate Updates - iBio regained compliance with Nasdaq Listing Rule 5550(a)(2) on November 4, 2025 [7] - The company held cash, cash equivalents, and investments totaling $49.6 million as of September 30, 2025, which is expected to support operations into the fourth quarter of fiscal year 2027 [7][11] Product Development - The non-human primate data for IBIO-610 indicates a predicted human half-life of up to 100 days, supporting infrequent dosing and reinforcing its potential as a next-generation therapy for obesity and cardiometabolic diseases [2][7] - The findings from the studies presented at ObesityWeek® 2025 and PEGS Europe highlight IBIO-610's differentiated mechanism, enabling fat-selective weight loss and sustained weight maintenance after GLP-1 therapy discontinuation [7] Company Overview - iBio, Inc. is a biotech company focused on developing next-generation biopharmaceuticals for cardiometabolic diseases, obesity, cancer, and other challenging conditions using AI and advanced computational biology [5]